July 15, 2011
A Pennsylvania federal judge on Friday approved a settlement between generics maker Teva Pharmaceuticals USA Inc. and Amgen Inc. that squashes Teva's hopes of marketing a copycat version of the blood drug Neopogen until 2013.
November 22, 2010
Pharmaceutical giant Amgen Inc. has lost its bid for partial summary judgment in a patent spat launched by Teva Pharmaceuticals USA Inc. as part of its effort to market a generic version of Amgen's blood drug Neupogen.